Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance - PubMed (original) (raw)
. 1998 Jun 4;338(23):1641-9.
doi: 10.1056/NEJM199806043382301.
Affiliations
- PMID: 9614254
- DOI: 10.1056/NEJM199806043382301
Free article
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance
A Pablos-Méndez et al. N Engl J Med. 1998.
Free article
Erratum in
- N England J Med 1998 Jul 9;339(2):139
Abstract
Background: Drug-resistant tuberculosis threatens efforts to control the disease. This report describes the prevalence of resistance to four first-line drugs in 35 countries participating in the World Health Organization-International Union against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance between 1994 and 1997.
Methods: The data are from cross-sectional surveys and surveillance reports. Participating countries followed guidelines to ensure the use of representative samples, accurate histories of treatment, standardized laboratory methods, and common definitions. A network of reference laboratories provided quality assurance. The median number of patients studied in each country or region was 555 (range, 59 to 14,344).
Results: Among patients with no prior treatment, a median of 9.9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7.3 percent) or streptomycin (6.5 percent) was more common than resistance to rifampin (1.8 percent) or ethambutol (1.0 percent). The prevalence of primary multidrug resistance was 1.4 percent (range, 0 to 14.4 percent). Among patients with histories of treatment for one month or more [corrected], the prevalence of resistance to any of the four drugs was 36.0 percent (range, 5.3 to 100 percent), and the prevalence of multidrug resistance was 13 percent (range, 0 to 54 percent). The overall prevalences were 12.6 percent for resistance to any of the four drugs [corrected] (range, 2.3 to 42.4 percent) and 2.2 percent for multidrug resistance (range, 0 to 22.1 percent). Particularly high prevalences of multidrug resistance were found in the former Soviet Union, Asia, the Dominican Republic, and Argentina.
Conclusions: Resistance to antituberculosis drugs was found in all 35 countries and regions surveyed, suggesting that it is a global problem.
Comment in
- The global threat of drug-resistant tuberculosis.
Snider DE Jr, Castro KG. Snider DE Jr, et al. N Engl J Med. 1998 Jun 4;338(23):1689-90. doi: 10.1056/NEJM199806043382309. N Engl J Med. 1998. PMID: 9614262 No abstract available. - Antituberculosis-drug resistance.
Chan-Tack KM. Chan-Tack KM. N Engl J Med. 1998 Oct 8;339(15):1079; author reply 1080. doi: 10.1056/NEJM199810083391511. N Engl J Med. 1998. PMID: 9766993 No abstract available. - Antituberculosis-drug resistance.
Diaz JF. Diaz JF. N Engl J Med. 1998 Oct 8;339(15):1079; author reply 1080. N Engl J Med. 1998. PMID: 9766994 No abstract available. - Antituberculosis-drug resistance.
Geerligs WA, van Altena R, van der Werf TS. Geerligs WA, et al. N Engl J Med. 1998 Oct 8;339(15):1079-80. N Engl J Med. 1998. PMID: 9766995 No abstract available.
Similar articles
- Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC. Espinal MA, et al. N Engl J Med. 2001 Apr 26;344(17):1294-303. doi: 10.1056/NEJM200104263441706. N Engl J Med. 2001. PMID: 11320389 - Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis.
Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Aziz MA, et al. Lancet. 2006 Dec 16;368(9553):2142-54. doi: 10.1016/S0140-6736(06)69863-2. Lancet. 2006. PMID: 17174706 - [Resistance and multiresistance to antitubercular drugs in Argentina and in other Latin American countries].
de Kantor IN, Latini O, Barrera L. de Kantor IN, et al. Medicina (B Aires). 1998;58(2):202-8. Medicina (B Aires). 1998. PMID: 9706257 Spanish. - [Drug resistant tuberculosis].
Zwolska Z, Augustynowicz-Kopeć E. Zwolska Z, et al. Pol Merkur Lekarski. 2011 May;30(179):362-6. Pol Merkur Lekarski. 2011. PMID: 21675144 Review. Polish.
Cited by
- Prevalence of multidrug-resistant and extensively drug-resistant tuberculosis in patients with pulmonary tuberculosis in zahedan, southeastern iran.
Metanat M, Sharifi-Mood B, Shahreki Sh, Dawoudi SH. Metanat M, et al. Iran Red Crescent Med J. 2012 Jan;14(1):53-5. Epub 2012 Jan 1. Iran Red Crescent Med J. 2012. PMID: 22737557 Free PMC article. No abstract available. - TSH-CHECK-1 test: diagnostic accuracy and potential application to initiating treatment for hypothyroidism in patients on anti-tuberculosis drugs.
Kosack CS, Page AL, Van Hulsteijn LT, Lentjes EG. Kosack CS, et al. PLoS One. 2012;7(3):e33704. doi: 10.1371/journal.pone.0033704. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442713 Free PMC article. - Protection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine model.
Lee S, Jeon BY, Bardarov S, Chen M, Morris SL, Jacobs WR Jr. Lee S, et al. Infect Immun. 2006 Nov;74(11):6491-5. doi: 10.1128/IAI.00531-06. Infect Immun. 2006. PMID: 17057098 Free PMC article. - Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC, Salomon JA, Murray M, Weinstein MC. Resch SC, et al. PLoS Med. 2006 Jul;3(7):e241. doi: 10.1371/journal.pmed.0030241. PLoS Med. 2006. PMID: 16796403 Free PMC article. - Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.
Faustini A, Hall AJ, Perucci CA. Faustini A, et al. Thorax. 2006 Feb;61(2):158-63. doi: 10.1136/thx.2005.045963. Epub 2005 Oct 27. Thorax. 2006. PMID: 16254056 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical